Madison-based Propeller Health and global pharmaceutical company Boehringer Ingelheim Pharmaceuticals Inc. said Wednesday they have forged a first-of-its-kind partnership that will use digital health tools to help people living with chronic repiratory diseases.

The partnership offers a new program to chronic obstructive pulmonary disease (COPD) and asthma patients who are being treated with a Boehringer Ingelheim medicine that can be used in the company’s inhaler. The program will evaluate how Propeller’s technology impacts adherence rates and patient engagement. Read the full Milwaukee Journal Sentinel story here.